Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Shiow-Lin Pan, Ph.D.

Assistant Investigator
Institute of Biotechnology and Pharmaceutical Research
apan0826@nhri.org.tw

EDUCATION

Ph.D., Pharmacology, National Taiwan University, Taipei, Taiwan (1998-2002)
M.S., Pharmacology, Taipei Medical University, Taipei, Taiwan (1992-1994)

PROFESSIONAL EXPERIENCES

Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health research Institutes, Miaoli, Taiwan (2009-present)
Assisstant Professor, Pharmacological Institute, College of Medicine, Taipei Medical University, Taipei, Taiwan (2008)
Assisstant Researcher, Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan (2007-2009)
Post-doctoral research scholar, Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan (2004-2007)
Postdoctoral fellow, Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan (2002-2004)
Assistant, Department of Physiology and Pharmacology, Chang-Gung University, Taoyuan, Taiwan (1994-1998)

RESEARCH INTERESTS

Dr. Shiow-Lin Pan’sresearch interest has focused mainly in the area of basic research for
drug development, particularly at the pre-clinical stage. She has published more than fifty
scientific papers on international journals and participated extensively in the research and
development of biomedicine for drug discovery, biotechnological product invention, and the studies
of new drug. In the R&D process, Dr. Pan is often involved in the pre-clinical development group
studies, in both animal research (mouse) facility and molecular biology laboratory. In addition to
the advancement of knowledge in basic science and the establishment of animal models for
translational medicine, she will focus on the signaling pathways known to induce tumors that are
critical to targeted therapy in the future.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Shiow-Lin Pan has made long-term commitment in basic research of drug development and has been
granted several drug patents in Taiwan and internationally to date, including those for the
treatment of inflammation, sepsis, angiogenesis and cancer disease, respectively. Dr. Pan carries
out basic research to tease out the causes, the origins and the mechanisms of illnesses and
diseases. Through pharmacological screening, she also studies in new compounds discovery, including
anticancer, antiagiogenesis or antimetastasis agents. These agents are optimized now and the
research findings were published in international journals. In terms of Dr. Pan’s research
achievements, she has published 35 SCI papers in 5 years, mostly in international journals, which
fully demonstrated Dr. Pan’s research potential in cancer research. To understand complex
biological phenomena and the process of disease development, it requires the application of animal
model and proper data analysis. As a result, many profound problems regarding disease process are
addressed because of the cutting-edge studies done on appropriate animal models. Dr. Pan’s
research has focused on the implementation and application of anti-cancer, anti-restenosis (balloon
injury), and anti-sepsis animal models. So far Dr. Pan has collected approximately 50 commissioned
cases; each of them has been conducted according to the Standard Operating Procedures (SOP) and
maintained a case report.

HONORS & AWARDS

13th International Congress of Mucosal Immunology: A Prize for the Travel Award, 2007
Outstanding Thesis Award, the Pharmacological Society in Taiwan, 2004
Industry-Academy Cooperation Award, the Ministry of Education, Taiwan, 2003

SELECTED PUBLICATIONS

1. Pan SL, Guh JH, Peng CY, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, Teng CM.. A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models.. Thromb Haemost. 93:940-948, 2005.
2. Liao CH, Pan SL, Guh JH, Chang YL, Pai HC, Lin CH, Teng CM.. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae Fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo.. Carcinogenesis. 26:968-975, 2005.
3. Chiang PC, Chien CL, Pan SL, Chen WP, Teng CM, Shen YC, Guh JH.. Induction of endoplasmic reticulum stress and apoptosis by a marine prostanoid in human hepatocellular carcinoma.. J Hepatol. 43:679-686, 2005.
4. Wang SW, Pan SL, Guh JH, Chen HL, Huang DM, Chang YL, Kuo SC, Lee FY, Teng CM.. YC-1 [3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells.. J Pharmacol Exp Ther. 312:917-925, 2005.
5. Pan SL, Guh JH, Peng CY, Wang SW, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, Teng CM.. YC-1 [3-(5-Hydroxymethyl-2-Furyl)-1-Benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors In Vitro and Angiogenesis In Vivo Models.. J Pharmacol Exp Ther. 314:35-42, 2005.
6. Huang YT, Pan SL, Guh JH, Chang YL, Lee FY, Kuo SC, Teng CM.. YC-1 constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells.. Mol Cancer Ther. 4:1628-1635, 2005.
7. Chiang PC, Kung FL, Huang DM, Li TK, Fan JR, Pan SL, Shen YC, Guh JH.. Induction of Fas clustering and apoptosis by coral prostanoid in human hormone-resistant prostate cancer cells.. Eur J Pharmacol. 542:22-30, 2006.
8. Huang LJ, Shih ML, Chen HS, Pan SL, Teng CM, Lee FY, Kuo SC.. Synthesis of N(2)-(substituted benzyl)-3-(4-methylphenyl)indazoles as novel anti-angiogenic agents.. Bioorg Med Chem. 14:528-536, 2006.
9. Liu YN*, Pan SL*, Peng CY, Guh JH, Huang DM, Chang YL, Lin CH, Pai HC, Kuo SC, Lee FY, Teng CM.. YC-1 Inhibits Neointima Formation in Balloon-Injured Rat Carotid Through Suppression of Expressions and Activities of MMP-2 and MMP-9.. J Pharmacol Exp Ther. 316:35-41, 2006.
10. Hsu MH, Chen CJ, Kuo SC, Chung JG, Lai YY, Teng CM, Pan SL, Huang LJ.. 2-(3-Fluorophenyl)-6-methoxyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (YJC-1) induces mitotic phase arrest in A549 cells.. Eur J Pharmacol. 559:14-20, 2007.
11. Wei L, Shi Q, Bastow KF, Brossi A, Morris-Natschke SL, Nakagawa-Goto K, Wu TS, Pan SL, Teng CM, Lee KH.. Antitumor Agents 253. Design, Synthesis, and Antitumor Evaluation of Novel 9-Substituted Phenanthrene-Based Tylophorine Derivatives as Potential Anticancer Agents.. J Med Chem. 50:3674-3680, 2007.
12. Wei L, Shi Q, Bastow KF, Brossi A, Morris-Natschke SL, Nakagawa-Goto K, Wu TS, Pan SL, Teng CM, Lee KH.. Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.. J Med Chem. 50:3674-3680, 2007.
13. Wang SW, Pan SL, Peng CY, Huang DY, Tsai AC, Chang YL, Guh JH, Kuo SC, Lee KH, Teng CM.. CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. Cancer Lett. 257:87-96, 2007.
14. Lu PH, Chueh SC, Kung FL, Pan SL, Shen YC, Guh JH.. Ilimaquinone, a marine sponge metabolite, displays anticancer activity via GADD153-mediated pathway.. Eur J Pharmacol. 556:45-54, 2007.
15. Chen YC, Lu PH, Pan SL, Teng CM, Kuo SC, Lin TP, Ho YF, Huang YC, Guh JH.. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.. Biochem Pharmacol. 74:10-19, 2007.
16. Chen YC, Lu PH, Pan SL, Teng CM, Kuo SC, Lin TP, Ho YF, Huang YC, Guh JH.. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.. Biochem Pharmacol. 74:10-19, 2007.
17. Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH, Lee FY, Kuo SC, Teng CM.. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.. Oncogene. 26:3941-3951, 2007.
18. Peng CY, Pan SL*, Huang YW, Guh JH, Chang YL, Teng CM*.. Baicalein attenuates intimal hyperplasia after rat carotid balloon injury through arresting cell-cycle progression and inhibiting ERK, Akt, and NF-kappaB activity in vascular smooth-muscle cells.. Naunyn Schmiedebergs Arch
Pharmacol. 378:579-588, 2008.
19. Wang SW, Pan SL, Huang YC, Guh JH, Chiang PC, Huang DY, Kuo SC, Lee KH, Teng CM.. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo.. Mol Cancer Ther. 7:350-360, 2008.
20. Chen TH, Pan SL*, Guh JH, Chen CC, Huang YT, Pai HC, Teng CM*. Denbinobin induces apoptosis by apoptosis-inducing factor releasing and DNA damage in human 91/01/18 ?? colorectal cancer HCT-116 cells.. Naunyn Schmiedebergs Arch Pharmacol. 378:447-457, 2008.
21. Kuo CT, Hsu MJ, Chen BC, Chen CC, Teng CM, Pan SL, Lin CH.. Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction.. Toxicol Lett. 177:48-58, 2008.
22. Chiang PC, Hsu JL, Yeh TC, Pan SL, Guh JH.. Elucidation of susceptible factors to endoplasmic reticulum stress-mediated anticancer activity in human hepatocellular carcinoma.. Naunyn Schmiedebergs Arch Pharmacol. 377:167-177, 2008.
23. Peng CY, Pan SL, Lee KH, Bastow KF, Teng CM.. Molecular mechanism of the inhibitory effect of KS-5 on bFGF-induced angiogenesis in vitro and in vivo.. Cancer Lett. 263:114-121, 2008.
24. Chen TH*, Pan SL*, Guh JH, Liao CH, Huang DY, Chen CC, Teng CM. Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-Jun NH2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage.. Clin Cancer Res. 14:4250-4258, 2008.
25. Pan SL, Tao KY, Guh JH, Sun HL, Huang DY, Chang YL, Teng CM.. THE P38 MITOGENACTIVATED PROTEIN KINASE PATHWAY PLAYS A CRITICAL ROLE IN PAR2-INDUCED ENDOTHELIAL IL-8 PRODUCTION AND LEUKOCYTE ADHESION.. Shock. 30:496-502, 2008.
26. Liu YN, Pan SL, Peng CY, Huang DY, Guh JH, Kuo SC, Lee FY, Teng CM.. YC-1 INDUCES HEAT SHOCK PROTEIN 70 EXPRESSION AND PREVENTS OXIDIZED LDLMEDIATED
APOPTOSIS IN VASCULAR SMOOTH MUSCLE CELLS.. Shock. 30:274-279, 2008.
27. Wu SY*, Pan SL*, Chen TH, Liao CH, Huang DY, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM.. YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway.. Br J Pharmacol. 155:505-513, 2008.
28. Kuo CT, Chen BC, Yu CC, Weng CM, Hsu MJ, Chen CC, Chen MC, Teng CM, Pan SL, Bien MY, Shih CH, Lin CH.. Apoptosis signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung adenocarcinoma cells.. J Biomed Sci. 16:43-57, 2009.
29. Sun HL, Tsai AC, Pan SL, Ding Q, Yamaguchi H, Lin CN, Hung MC, Teng CM.. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation.. Clin Cancer Res. 15:4904-4914, 2009.
30. Liu YN, Pan SL, Liao CH, Huang DY, Guh JH, Peng CY, Chang YL, Teng CM.. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7.. Shock. 32:263-269, 2009.
31. Chiang PC, Lin SC, Pan SL, Kuo CH, Tsai IL, Kuo MT, Wen WC, Chen P, Guh JH.. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways. Biochem Pharmacol. 79:162-171, 2010.
32. Tsai AC, Pan SL*, Sun HL, Wang CY, Peng CY, Wang SW, Chang YL, Kuo SC, Lee KH, Teng CM*.. CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via P53-mediated death receptor 5 upregulatio.. J Biol Chem. in press:-, 2010.
33. Liu YN*, Pan SL*, Peng CY, Huang DY, Guh JH, Chen CC, Shen CC, Teng CM. Moscatilin Repressed Lipopolysaccaride-Induced HIF-1alpha accumulation and NF-kappaB Activation in Murine RAW264.7 Cells.. Shock. 33:70-75, 2010.
34. Tsai AC, Pan SL*, Wang SW, Guh JH, Sun HL, Liu YN, Liao CH, Chen CC, Teng CM*.. Moscatilin, a Novel Anti-angionenic Agent, Induced Cell Cycle Arrest and Apoptosis in Human Umbilical Vein Endothelial Cells.. Cancer Lett. in press:-, 2010.

PATENT

1. USA 7166293 (2002) Angiogenesis inhibitors.. Teng; Che-Ming, Kuo; Sheng-Chu, Lee; Fang Yu, Pan; Shiow-Lin, Guh; Jih-Hwa.
2. USA 6943186 (2003) Methods of treating sepsis.. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
3. European 03250418.5-2101 (2003) Methods of treating sepsis.. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
4. USA 7378532 (2004) Fused pyrazolyl compound.. Kuo; Sheng-Chu, Lee; Fang-Yu, Teng; Che-Ming, Huang; Li-Jiau, Chou; Li-Chen, Guh; Jih-Hwa, Pan; Shiow-Lin.
5. European 05291767.1 (2005) Anti-angiogenesis methods. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
6. European 05290694.8 (2005) Novel fused pyrazolyl compound. Kuo; Sheng-Chu, Lee; Fang-Yu, Teng; Che-Ming, Huang; Li-Jiau, Chou; Li-Chen, Guh; Jih-Hwa, Pan; Shiow-Lin.
7. European 05290569.2 (2005) Preferential inhibition of release of pro-inflammatory cytokines. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
8. European 06126873.6-2107 (2006) Cancer chemotherapy. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
9. New Zealand (2006) Cancer treatment. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
10. European 06113936.6 (2006) Cancer treatment. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
11. ROC 296524 (2008) ???????. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.
12. ROC 293027 (2008) ??????????????????????????????.. Teng; Che-Ming, Pan; Shiow-Lin, Guh; Jih-Hwa, Kuo; Sheng-Chu, Lee; Fang-Yu.